GB0019728D0 - Novel treatment - Google Patents

Novel treatment

Info

Publication number
GB0019728D0
GB0019728D0 GBGB0019728.5A GB0019728A GB0019728D0 GB 0019728 D0 GB0019728 D0 GB 0019728D0 GB 0019728 A GB0019728 A GB 0019728A GB 0019728 D0 GB0019728 D0 GB 0019728D0
Authority
GB
United Kingdom
Prior art keywords
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0019728.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB0019728.5A priority Critical patent/GB0019728D0/en
Publication of GB0019728D0 publication Critical patent/GB0019728D0/en
Priority to UA2003021025A priority patent/UA79735C2/en
Priority to PT05077471T priority patent/PT1666487E/en
Priority to APAP/P/2003/002734A priority patent/AP2003002734A0/en
Priority to AT01960630T priority patent/ATE313558T1/en
Priority to IL15430101A priority patent/IL154301A0/en
Priority to DE60116107T priority patent/DE60116107T2/en
Priority to NZ524012A priority patent/NZ524012A/en
Priority to CN018169988A priority patent/CN1468256B/en
Priority to PL362322A priority patent/PL204736B1/en
Priority to CZ20030385A priority patent/CZ303217B6/en
Priority to AU2001282073A priority patent/AU2001282073B2/en
Priority to DZ013470A priority patent/DZ3470A1/en
Priority to DK05077471T priority patent/DK1666487T3/en
Priority to CA2427475A priority patent/CA2427475C/en
Priority to EP05077471A priority patent/EP1666487B1/en
Priority to BRPI0113155A priority patent/BRPI0113155C1/en
Priority to ES01960630T priority patent/ES2254464T3/en
Priority to AU8207301A priority patent/AU8207301A/en
Priority to SK169-2003A priority patent/SK288069B6/en
Priority to SK50032-2012A priority patent/SK288079B6/en
Priority to CA2740282A priority patent/CA2740282A1/en
Priority to DK01960630T priority patent/DK1307473T3/en
Priority to EA200300129A priority patent/EA006433B1/en
Priority to ES05077471T priority patent/ES2314555T3/en
Priority to EP01960630A priority patent/EP1307473B1/en
Priority to SI200130884T priority patent/SI1666487T1/en
Priority to OA1200300038A priority patent/OA12361A/en
Priority to DE60136400T priority patent/DE60136400D1/en
Priority to US10/344,211 priority patent/US20030235590A1/en
Priority to KR1020037001933A priority patent/KR100804922B1/en
Priority to JP2002518258A priority patent/JP2004505992A/en
Priority to MXPA03001235A priority patent/MXPA03001235A/en
Priority to AT05077471T priority patent/ATE412665T1/en
Priority to SI200130489T priority patent/SI1307473T1/en
Priority to PCT/EP2001/009100 priority patent/WO2002012287A1/en
Priority to HU0302951A priority patent/HU228932B1/en
Priority to PE2001000786A priority patent/PE20020287A1/en
Priority to ARP010103790A priority patent/AR030325A1/en
Priority to EG2001080869A priority patent/EG25829A/en
Priority to MYPI20013779A priority patent/MY128999A/en
Priority to UY26882A priority patent/UY26882A1/en
Priority to IL154301A priority patent/IL154301A/en
Priority to ZA200301046A priority patent/ZA200301046B/en
Priority to BG107545A priority patent/BG66038B1/en
Priority to NO20030635A priority patent/NO20030635L/en
Priority to HK03107371A priority patent/HK1056884A1/en
Priority to US11/266,565 priority patent/US20060159705A1/en
Priority to CY20061100311T priority patent/CY1106310T1/en
Priority to CY20081101440T priority patent/CY1108789T1/en
Priority to US12/342,220 priority patent/US8624004B2/en
Priority to JP2012180462A priority patent/JP5559847B2/en
Priority to NO20130773A priority patent/NO337659B1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0019728.5A 2000-08-10 2000-08-10 Novel treatment Ceased GB0019728D0 (en)

Priority Applications (53)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment
UA2003021025A UA79735C2 (en) 2000-08-10 2001-07-08 Purification of hbv antigens for use in vaccines
PT05077471T PT1666487E (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
APAP/P/2003/002734A AP2003002734A0 (en) 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines.
AT01960630T ATE313558T1 (en) 2000-08-10 2001-08-07 PURIFICATION OF HBV ANTIGENS FOR USE IN VACCINES
IL15430101A IL154301A0 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
DE60116107T DE60116107T2 (en) 2000-08-10 2001-08-07 CLEANING OF HBV ANTIGENES FOR USE IN VACCINES
NZ524012A NZ524012A (en) 2000-08-10 2001-08-07 Hepatitis B antigen preparation comprising less than 0.025 micrograms of mercury per 20 micrograms protein
CN018169988A CN1468256B (en) 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines
PL362322A PL204736B1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
CZ20030385A CZ303217B6 (en) 2000-08-10 2001-08-07 Process for preparing hepatitis B virus vaccine
AU2001282073A AU2001282073B2 (en) 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines
DZ013470A DZ3470A1 (en) 2000-08-10 2001-08-07 PURIFICATION OF HBV ANTIGENS FOR VACCINES
DK05077471T DK1666487T3 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
CA2427475A CA2427475C (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
EP05077471A EP1666487B1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
BRPI0113155A BRPI0113155C1 (en) 2000-08-10 2001-08-07 methods for producing a hepatitis b vaccine and a hepatitis b surface antigen
ES01960630T ES2254464T3 (en) 2000-08-10 2001-08-07 PURIFICATION OF HBV ANTIGENS FOR USE IN VACCINES.
AU8207301A AU8207301A (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
SK169-2003A SK288069B6 (en) 2000-08-10 2001-08-07 Process for preparing hepatitis B virus vaccine
SK50032-2012A SK288079B6 (en) 2000-08-10 2001-08-07 Method for preparing stable, immunogenic hepatitis B vaccine without trace of thiomersal
CA2740282A CA2740282A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
DK01960630T DK1307473T3 (en) 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines
EA200300129A EA006433B1 (en) 2000-08-10 2001-08-07 Method for production of surface hepatitis b antigen and comprising it vaccine compositions
ES05077471T ES2314555T3 (en) 2000-08-10 2001-08-07 PURIFICATION OF VHB ANTIGENS FOR USE IN VACCINES.
EP01960630A EP1307473B1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
SI200130884T SI1666487T1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
OA1200300038A OA12361A (en) 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines.
DE60136400T DE60136400D1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
US10/344,211 US20030235590A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
KR1020037001933A KR100804922B1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
JP2002518258A JP2004505992A (en) 2000-08-10 2001-08-07 Purification of HBV antigens for use in vaccines
MXPA03001235A MXPA03001235A (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines.
AT05077471T ATE412665T1 (en) 2000-08-10 2001-08-07 PURIFICATION OF HBV ANTIGENS FOR USE IN VACCINES
SI200130489T SI1307473T1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
PCT/EP2001/009100 WO2002012287A1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
HU0302951A HU228932B1 (en) 2000-08-10 2001-08-07 Purification of hbv antigens for use in vaccines
PE2001000786A PE20020287A1 (en) 2000-08-10 2001-08-08 PROCEDURE FOR THE PURIFICATION OF AN ANTIGEN OF THE HEPATITIS B VIRUS
ARP010103790A AR030325A1 (en) 2000-08-10 2001-08-08 PROCEDURE TO PRODUCE AN ANTIGEN OF HEPATITIS B SUITABLE FOR USE IN A VACCINE, IMMUNOGENIC ANTIGEN OF HEPATITIS B THAT CAN BE OBTAINED BY THE PREVIOUS PROCEDURE AND VACCINE COMPOSITION THAT INCLUDES SUCH ANTIGEN
EG2001080869A EG25829A (en) 2000-08-10 2001-08-08 Novel treatment
MYPI20013779A MY128999A (en) 2000-08-10 2001-08-10 Purification of hbv antigens for use in vaccines
UY26882A UY26882A1 (en) 2000-08-10 2001-08-10 NEW TREATMENT
IL154301A IL154301A (en) 2000-08-10 2003-02-05 Purification of hbv antigens for use in vaccines
ZA200301046A ZA200301046B (en) 2000-08-10 2003-02-06 Purification of HBV antigens for use in vaccines.
BG107545A BG66038B1 (en) 2000-08-10 2003-02-07 Purification of hbv antigens for use in vaccines
NO20030635A NO20030635L (en) 2000-08-10 2003-02-07 Purification of HBV antigens for use in vaccines
HK03107371A HK1056884A1 (en) 2000-08-10 2003-10-14 Purification of hbv antigens for use in vaccines
US11/266,565 US20060159705A1 (en) 2000-08-10 2005-11-03 Purification of HBV antigens for use in vaccines
CY20061100311T CY1106310T1 (en) 2000-08-10 2006-03-07 DETERMINATION OF HBV ANTIGONS FOR USE IN VACCINES
CY20081101440T CY1108789T1 (en) 2000-08-10 2008-12-10 CLEANING HBV ANTIGENS FOR USE IN VACCINES
US12/342,220 US8624004B2 (en) 2000-08-10 2008-12-23 Purification of HBV antigens for use in vaccines
JP2012180462A JP5559847B2 (en) 2000-08-10 2012-08-16 Purification of HBV antigens for use in vaccines
NO20130773A NO337659B1 (en) 2000-08-10 2013-06-04 Method of Preparing a Vaccine.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0019728.5A GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment

Publications (1)

Publication Number Publication Date
GB0019728D0 true GB0019728D0 (en) 2000-09-27

Family

ID=9897396

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0019728.5A Ceased GB0019728D0 (en) 2000-08-10 2000-08-10 Novel treatment

Country Status (3)

Country Link
GB (1) GB0019728D0 (en)
NO (1) NO337659B1 (en)
ZA (1) ZA200301046B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111110876A (en) * 2020-01-20 2020-05-08 华兰生物工程重庆有限公司 Specific human immunoglobulin virus inactivation process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
ES2273482T3 (en) * 1998-03-09 2007-05-01 Glaxosmithkline Biologicals S.A. COMPOSITIONS OF COMBINED VACCINES.

Also Published As

Publication number Publication date
ZA200301046B (en) 2004-05-06
NO337659B1 (en) 2016-05-30
NO20130773L (en) 2003-04-01

Similar Documents

Publication Publication Date Title
GB0028264D0 (en) Well treatment
GB0028269D0 (en) Well treatment
EP1296697A4 (en) Therapeutic agents - i
IL150544A0 (en) Novel biarylcarboxamides
GB0112343D0 (en) Well treatment
AU8860401A (en) Novel guanidinobenzamides
GB0028429D0 (en) Therapy
EG25829A (en) Novel treatment
PL362855A1 (en) Improved treatment
GB0030845D0 (en) Novel treatment
GB9925136D0 (en) Novel treatment
AU1217102A (en) Novel arylalkane-sulfonamides
PL349347A1 (en) Novel treatment
AU8197001A (en) Novel arylethene-sulfonamides
GB0029125D0 (en) Novel treatment
GB0103031D0 (en) Novel treatment
GB0031321D0 (en) Treatment
GB0019728D0 (en) Novel treatment
GB0022992D0 (en) Novel vompounds
GB0006974D0 (en) Novel treatment
GB0029127D0 (en) Novel treatment
GB0029122D0 (en) Novel treatment
GB0006415D0 (en) Treatment
GB0012793D0 (en) Treatment
GB0012760D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)